(Q38166456)

30 August 2017

0 references

Genetics of antipsychotic-induced weight gain: update and current perspectives (English)

1 reference

30 August 2017

1 reference

Amy C C Kao

1

1 reference

PubMed ID

24279860

30 August 2017

Daniel J Müller

series ordinal

2

1 reference

PubMed ID

24279860

30 August 2017

language of work or name

1 reference

1 December 2013

1 reference

30 August 2017

1 reference

30 August 2017

14

1 reference

30 August 2017

16

1 reference

30 August 2017

2067-2083

1 reference

Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics.

30 August 2017

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Pharmacogenetics of leptin in antipsychotic-associated weight gain and obesity-related complications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

History of the discovery of the antipsychotic dopamine D2 receptor: a basis for the dopamine hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Genetics of antipsychotic treatment emergent weight gain in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Pharmacogenetic testing to predict antipsychotic-induced weight gain: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Pharmacogenetics of antipsychotic-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical Review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Genetic Polymorphisms in the HTR2C and Peroxisome Proliferator-Activated Receptors Are Not Associated with Metabolic Syndrome in Patients with Schizophrenia Taking Clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

5-HT2C receptor gene polymorphisms associated with antipsychotic drug action alter promoter activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Functional consequences of two HTR2C polymorphisms associated with antipsychotic-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Possible impact of ADRB3 Trp64Arg polymorphism on BMI in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Clozapine-induced alteration of glucose homeostasis in the rat: the contribution of hypothalamic-pituitary-adrenal axis activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

The TBC1D1 gene: structure, function, and association with obesity and related traits

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Exercise increases TBC1D1 phosphorylation in human skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

The Rab-GTPase-activating protein TBC1D1 regulates skeletal muscle glucose metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Tbc1d1 mutation in lean mouse strain confers leanness and protects from diet-induced obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

TBC1D1 is a candidate for a severe obesity gene and evidence for a gene/gene interaction in obesity predisposition

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Clozapine activates AMP-activated protein kinase (AMPK) in C2C12 myotube cells and stimulates glucose uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Exploratory study on association of genetic variation in TBC1D1 with antipsychotic-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

A critical role for beta cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Catechol-O-methyltransferase: characteristics, polymorphisms and role in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Folate, homocysteine, interleukin-6, and tumor necrosis factor alfa levels, but not the methylenetetrahydrofolate reductase C677T polymorphism, are risk factors for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

MTHFR and risk of metabolic syndrome in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

The effects of DBH, MAOA, and MAOB on attentional biases for facial expressions.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

The current state of play on the molecular genetics of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Catechol-O-methyl transferase and expression of schizophrenia in 73 adults with 22q11 deletion syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Cardiometabolic risk and the MTHFR C677T variant in children treated with second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Ghrelin induces adiposity in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

AMPK and the neuroendocrine regulation of appetite and energy expenditure

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Association study between variants of AMP-activated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Association between ghrelin gene (GHRL) polymorphisms and clinical response to atypical antipsychotic drugs in Han Chinese schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Mutations in ligands and receptors of the leptin-melanocortin pathway that lead to obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Positional cloning of the mouse obese gene and its human homologue

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Distribution of corticotropin-releasing factor receptors in primate brain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

The Q223R polymorphism in LEPR is associated with obesity in Pacific Islanders

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Association of a functional polymorphism in neuropeptide Y with antipsychotic-induced weight gain in schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Characterization of the hyperphagic response to dietary fat in the MC4R knockout mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Association of the common MC4R rs17782313 polymorphism with antipsychotic-related weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Characteristics of BDNF-induced weight loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Effects of olanzapine on brain-derived neurotrophic factor gene promoter activity in SH-SY5Y neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Pharmacogenetics of response to antipsychotics in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Association study of brain-derived neurotrophic factor gene polymorphisms and body weight change in schizophrenic patients under long-term atypical antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

The neurodevelopmental hypothesis of schizophrenia, revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

A theoretical molecular network for dyslexia: integrating available genetic findings

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Increased feeding and body weight gain in rats after acute and chronic activation of RXFP3 by relaxin-3 and receptor-selective peptides: functional and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

The pharmacogenetics of antipsychotic-induced adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

On the clinical relevance of clozapine-triggered release of cytokines and soluble cytokine-receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Anti-inflammatory drugs in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Association between the ROBO1 gene and body mass index in patients using antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

On the replication of genetic associations: timing can be everything!

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Relaxin family peptide systems and the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Relaxin polymorphisms associated with metabolic disturbance in patients treated with antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

TNF-α -308 G>A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Genetic association between TNF-alpha -308 G>A polymorphism and longitudinal weight change during clozapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Evidence for an effect of clozapine on the regulation of fat-cell derived factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Weight gain and ghrelin level after olanzapine monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

INSIG1 influences obesity-related hypertriglyceridemia in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Sterol-induced degradation of HMG CoA reductase depends on interplay of two Insigs and two ubiquitin ligases, gp78 and Trc8.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

AMPK: a nutrient and energy sensor that maintains energy homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Peroxisome proliferator-activated receptor gamma (PPARG) Pro12Ala: lack of association with weight gain in psychiatric inpatients treated with olanzapine or clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Stress and affective disorders: animal models elucidating the molecular basis of neuroendocrine-behavior interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Variation in FTO contributes to childhood obesity and severe adult obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

The genetics of obesity: FTO leads the way.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

The obesity risk gene FTO influences body mass in chronic schizophrenia but not initial antipsychotic drug-induced weight gain in first-episode patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

A common genetic variant is associated with adult and childhood obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Performance of a neuro-fuzzy model in predicting weight changes of chronic schizophrenic patients exposed to antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Using a pharmacogenomic algorithm to guide the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Proteomic profiling in schizophrenia: enabling stratification for more effective treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Interventions for the metabolic syndrome in schizophrenia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

R125W coding variant in TBC1D1 confers risk for familial obesity and contributes to linkage on chromosome 4p14 in the French population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.207

21 January 2018

Identifiers

DOI

10.2217/PGS.13.207

1 reference

30 August 2017

1 reference

PubMed ID

24279860